Thomas Weisel

Analyst Tim Klasell of Thomas Weisel maintains his "overweight" rating on Microsoft Corporation (NASDAQ: MSFT), while raising his estimates for the company. The target price for MSFT has been raised from $31 to $35. According to Thomas Weisel, Microsoft has reduced its cost structure, while the...

Technology titan Microsoft (NASDAQ: MSFT) may see improved prospects in the coming year. Analysts at Thomas Weisel have revised their estimates and have rated the stock as Overweight. The price target has been set at $35.00. Improved outlook for hardware shipments, an improving external...

OncoGenex Pharmaceuticals has announced its global license and collaboration agreement with Teva (NASDAQ: TEVA) to develop and commercialize OGX-011. The agreement makes OncoGenex eligible for $60 million upfront and up to $370 million in milestone payments related to regulatory targets, apart from...

Analysts at Thomas Weisel initiate coverage of MasterCard Inc (NYSE: MA) with an "overweight" rating. The target price for MA is set to $305. According to Thomas Weisel, MasterCard is expected to benefit significantly from the ongoing shift from cash to electronic forms of payment. MA is leveraged...

Analysts at Thomas Weisel initiate coverage of Visa Inc (NYSE: V) with an "overweight" rating. The target price for V is set to $102. According to Thomas Weisel, Visa is expected to benefit significantly from the ongoing shift from cash to electronic forms of payment and an improving economic...

Thomas Weisel retained its overweight rating and increased its price target from $85 to $90 for Research In Motion Limited (NASDAQ: RIMM). The increase in price target was attributed to strong F3Q results and better than expected margin guidance for F4Q. It noted that the no. of units shipped,the...

Lincare Holdings (NASDAQ: LNCR) could face reimbursement uncertainty, according to a prediction by Thomas Weisel (NASDAQ: TWPG). Thomas Weisel predicted that a better entry point in the stock will occur in the future. It set a $28 target on the shares.

Psychiatric Solutions (NASDAQ: PSYS), as predicted by Thomas Weisel (NASDAQ: TWPG), will resume making acquisitions at the end of this year, after the credit freeze last year prevented it from making any. Thomas Weisel expects the resumption to be a catalyst for the stock and it set a $33 target on...

Thomas Weisel (NASDAQ: TWPG) feels that RehabCare (NYSE: RHB) is making good progress, but the firm thinks that RehabCare's plan to make a significant acquisition soon would place it in some uncertainty. The firm set a $24 target on the stock.

Thomas Weisel (NASDAQ: TWPG) is of the opinion that Emergency Medical (NYSE: EMS) would stand to gain from lower AMR costs and strong expansion in its emergency care services. Thomas Weisel feels that Emergency Medical can beat expected earnings by a wide margin. It set a $57 target on the stock.

Thomas Weisel (NASDAQ: TWPG) is impressed with VF Corp’s (NYSE: VFC) growth strategy, operating discipline, and opportunities to grow market share. This was announced after attending VF Corp's investor meetings. Thomas Weisel thinks the company's international growth opportunities are...

Thomas Weisel attended a meeting regarding the shortages of Genzyme’s Cerezyme treatment. Thomas Weisel said that it has more confidence in the company's 2009 guidance and its 2010 estimates. Thomas Weisel maintains an Overweight rating on the stock.

After meeting with NetLogic's (NASDAQ: NETL) CFO, Thomas Weisel is very comfortable retaining the company as its Top Pick. Thomas Weisel predicts that new wireless infrastructure deployments will allow the company to continue growing in 2009 and 2010, and it maintains an Overweight rating.